Rhumbline Advisers Raises Position in Tarsus Pharmaceuticals, Inc. $TARS

Rhumbline Advisers lifted its stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) by 4.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 51,682 shares of the company’s stock after buying an additional 2,148 shares during the period. Rhumbline Advisers owned approximately 0.12% of Tarsus Pharmaceuticals worth $2,655,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of TARS. GF Fund Management CO. LTD. purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $44,000. Amalgamated Bank boosted its holdings in Tarsus Pharmaceuticals by 30.1% in the first quarter. Amalgamated Bank now owns 1,274 shares of the company’s stock valued at $65,000 after purchasing an additional 295 shares during the last quarter. Quarry LP boosted its holdings in Tarsus Pharmaceuticals by 20.0% in the first quarter. Quarry LP now owns 3,599 shares of the company’s stock valued at $185,000 after purchasing an additional 599 shares during the last quarter. AlphaQuest LLC purchased a new position in Tarsus Pharmaceuticals in the first quarter valued at about $189,000. Finally, BNP Paribas Financial Markets purchased a new position in Tarsus Pharmaceuticals in the fourth quarter valued at about $268,000. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Tarsus Pharmaceuticals Stock Performance

Shares of NASDAQ TARS opened at $50.60 on Wednesday. The business’s 50-day moving average price is $49.04 and its two-hundred day moving average price is $46.63. The company has a debt-to-equity ratio of 0.22, a current ratio of 5.26 and a quick ratio of 5.21. Tarsus Pharmaceuticals, Inc. has a one year low of $30.23 and a one year high of $59.76. The company has a market capitalization of $2.14 billion, a P/E ratio of -21.72 and a beta of 0.81.

Tarsus Pharmaceuticals (NASDAQ:TARS) last issued its earnings results on Wednesday, August 6th. The company reported ($0.48) EPS for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Tarsus Pharmaceuticals had a negative net margin of 31.13% and a negative return on equity of 32.36%. The firm had revenue of $102.66 million during the quarter, compared to analysts’ expectations of $95.81 million. Analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TARS. Zacks Research raised Tarsus Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, September 5th. Oppenheimer initiated coverage on Tarsus Pharmaceuticals in a research note on Monday, June 2nd. They set an “outperform” rating and a $75.00 price objective on the stock. HC Wainwright raised Tarsus Pharmaceuticals to a “buy” rating and set a $72.00 price target on the stock in a report on Tuesday, May 27th. Finally, Wall Street Zen downgraded Tarsus Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Five analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $66.67.

Insider Transactions at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of the business’s stock in a transaction dated Monday, August 11th. The stock was sold at an average price of $50.00, for a total transaction of $300,000.00. Following the completion of the transaction, the chief executive officer owned 818,106 shares of the company’s stock, valued at approximately $40,905,300. The trade was a 0.73% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director William J. Phd Link sold 27,116 shares of the business’s stock in a transaction dated Monday, September 8th. The stock was sold at an average price of $57.00, for a total value of $1,545,612.00. Following the transaction, the director directly owned 143,332 shares of the company’s stock, valued at $8,169,924. This represents a 15.91% decrease in their position. The disclosure for this sale can be found here. 8.97% of the stock is owned by insiders.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.